Bayer receives marketing authorisation for Neptra in Europe

Bayer‘s Neptra treats susceptible strains of common pathogens found in canine otitis externa with just one vet-administered dose

19 December 2019, at 9:00am

Bayer‘s Neptra® ear drops solution for dogs (florfenicol, terbinafine hydrochloride, mometasone furoate) has now received a marketing authorisation for Europe.

Neptra® is approved for the treatment of acute canine otitis externa or acute exacerbations of recurrent otitis caused by mixed infections of susceptible strains of bacteria sensitive to florfenicol (Staphylococcus pseudintermedius) and fungi sensitive to terbinafine (Malassezia pachydermatis), by the European Commission.

“Otitis externa is a common disease in dogs and a leading cause why owners take their dog to a veterinarian,” says Mario Andreoli, Head of Marketing at Bayer Animal Health. “Neptra offers a key advantage, unlike competing products, it requires just one dose, administered by the veterinarian in the practice.”

No at-home applications by the dog owner are required. The treatment stays in the hands of the veterinarian and thus allows full control over compliance. “With Neptra we provide a high-quality veterinary treatment,” explains Andreoli, “that is convenient for the dog owner and ensures the well-being of dogs with a proper, effective application.”

Bayer Animal Health complements its veterinary product portfolio with an innovative product for the effective treatment of ear infections in dogs. Neptra will be available on the European market in early 2020.

Find more information on Bayer‘s website.